Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
- Conditions
- Interventions
- First Posted Date
- 2006-08-07
- Last Posted Date
- 2017-03-03
- Target Recruit Count
- 72
- Registration Number
- NCT00361140
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors
- Conditions
- Interventions
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT00357396
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
- Conditions
- Recurrent Childhood Acute Myeloid LeukemiaRefractory Anemia With Excess Blasts in TransformationRefractory AnemiaDe Novo Myelodysplastic SyndromeSecondary Myelodysplastic SyndromeChildhood Myelodysplastic SyndromeLeukemiaMyelodysplastic SyndromesSecondary Acute Myeloid LeukemiaRefractory Anemia With Excess Blasts
- Interventions
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 33
- Registration Number
- NCT00357565
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2010-05-14
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00346359
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis
- Conditions
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 288
- Registration Number
- NCT00334672
- Locations
- 🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom
🇬🇧Watford General Hospital, Herts, England, United Kingdom
🇬🇧Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
Respiratory Side Effects of Busulfan High Dose Chemotherapy in a Pediatric Population
- Conditions
- First Posted Date
- 2006-05-19
- Last Posted Date
- 2009-02-25
- Lead Sponsor
- University Hospital, Strasbourg, France
- Target Recruit Count
- 35
- Registration Number
- NCT00328029
- Locations
- 🇫🇷
Service de Pédiatrie Onco-Hématologie - Hôpital de Hautepierre, Strasbourg, France
🇫🇷Service d'Explorations Fonctionelles Respiratoires - Hôpital Civil, Strasbourg, France
Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia
- Conditions
- Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Myelodysplastic Syndrome With Isolated Del(5q)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Previously Treated Myelodysplastic SyndromesAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAcute Myeloid Leukemia/Transient Myeloproliferative DisorderAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Interventions
- Radiation: total-body irradiationProcedure: allogeneic hematopoietic stem cell transplantationDrug: mycophenolate mofetilDrug: cyclophosphamideDrug: cyclosporineDrug: busulfanDrug: fludarabine phosphateProcedure: peripheral blood stem cell transplantationProcedure: nonmyeloablative allogeneic hematopoietic stem cell transplantationOther: laboratory biomarker analysisGenetic: cytogenetic analysisOther: flow cytometryOther: pharmacological studyGenetic: fluorescence in situ hybridizationDrug: tacrolimusGenetic: polymorphism analysisDrug: methotrexate
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00322101
- Locations
- 🇺🇸
Weill Cornell University, New York, New York, United States
🇺🇸HealthOne Presbyterian St. Lukes Medical Center, Denver, Colorado, United States
🇺🇸Emory University, Altanta, Georgia, United States
Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma
- Conditions
- First Posted Date
- 2006-04-24
- Last Posted Date
- 2015-09-25
- Target Recruit Count
- 96
- Registration Number
- NCT00317408
- Locations
- 🇨🇿
University Hospital Brno, Brno, Czech Republic
🇧🇪U.Z. Gasthuisberg, Leuven, Belgium
🇩🇪Krankenhaus Muenchen Schwabing, Munich, Germany
Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2010-09-21
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT00313625
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2012-11-12
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 40
- Registration Number
- NCT00305708
- Locations
- 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.